SEC Form 10-Q Summary
Registrant and period: The filing is for Health Sciences Acquisitions Corporation, not Immunovant, Inc. It covers the unaudited quarter ended March 31, 2019 and was filed June 12, 2019. The registrant was a newly formed blank-check company incorporated December 6, 2018, focused on pursuing a healthcare, biopharma or medical technology business combination.
Financial condition and results
| Metric | March 31, 2019 | December 31, 2018 |
|---|---|---|
| Cash | $147,800 | $325,000 |
| Total assets | $324,550 | $405,000 |
| Current liabilities | $300,448 | $380,448 |
| Related-party promissory note | $300,000 | $300,000 |
| Stockholders’ equity | $24,102 | $24,552 |
- The company generated no operating revenue and had not commenced operations.
- Operating costs and net loss for the quarter were $450.
- Basic and diluted net loss per share was reported as $0.00, with weighted-average shares of 2,500,000.
- Net cash used in operating activities was $450.
- Net cash used in financing activities was $176,750, primarily reflecting payment of offering costs.
- Cash declined by $177,200 during the quarter, from $325,000 to $147,800.
- No operating, profit or margin metrics were meaningful because the company had no operations or revenue.
- As of March 31, 2019, the company reported no long-term debt, lease obligations or off-balance-sheet arrangements. The $300,000 related-party promissory note was current and non-interest-bearing.
Material changes and subsequent events
- Compared with December 31, 2018, cash decreased by $177,200, deferred offering costs increased from $80,000 to $176,750, and total liabilities decreased by $80,000 as accrued offering costs were paid.
- The accumulated deficit increased from $448 to $898, reflecting the $450 quarterly net loss.
- After quarter-end, on May 14, 2019, the company completed an initial public offering of 11,500,000 units at $10.00 per unit, generating gross proceeds of $115.0 million.
- Concurrent with the offering, the sponsor purchased 10,000,000 private warrants for $5.0 million.
- The company placed $115.0 million into a trust account and reported $2,322,592 outside the trust account for working capital after offering costs.
- Total offering transaction costs were $6,907,415, including $4,025,000 of deferred underwriting fees.
- The $300,000 related-party promissory note was repaid on May 15, 2019. A separate $50,000 sponsor advance made in May 2019 was also repaid on May 15, 2019.
Outlook, risks and unusual items
- Management expected to incur continuing legal, accounting, due diligence and public-company costs while searching for and negotiating a business combination.
- The company had until May 14, 2021 to complete a business combination. If unsuccessful, it was required to cease operations, redeem the public shares from the trust account and liquidate.
- Public stockholders generally had conversion rights in connection with a business combination, subject to the company’s net tangible asset requirement and other limitations.
- The company was required to pursue a target or targets with an aggregate fair market value of at least 80% of the trust account assets, excluding specified amounts.
- There was no assurance that a business combination would be completed. If the transaction failed, public warrants could expire worthless.
- Management stated that it did not expect to need additional funds for planned expenditures, but acknowledged that cost overruns, substantial shareholder redemptions or transaction financing needs could require additional capital, securities issuance or debt.
- The sponsor agreed to provide office space, utilities and administrative support for $10,000 per month beginning May 9, 2019 until the earlier of a business combination or liquidation.
- Management reported effective disclosure controls and procedures as of March 31, 2019 and no material change in internal control over financial reporting.
- No legal proceedings were reported, and the filing stated that there were no material changes to the risk factors previously disclosed in the IPO prospectus.
Investor verification points
- Verify the issuer identity: the supplied filing is for Health Sciences Acquisitions Corporation, while the request identifies Immunovant, Inc.
- Confirm the subsequent IPO, trust-account balance, offering expenses and cash held outside the trust account using the May 2019 filings.
- Review the applicable IPO prospectus for redemption terms, sponsor protections, warrant dilution and the May 14, 2021 business-combination deadline.
- Assess the sponsor’s related-party arrangements, including founder shares, private warrants, the repaid promissory note and the $10,000 monthly administrative fee.
- Determine whether a subsequent business combination occurred and whether the company later became or was affiliated with Immunovant.